APX Acquisition I announced today that it has signed a non-binding letter of intent for a proposed business combination with an unnamed precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and prevents disease.
The target is focused on the Spanish speaking global population through its diagnostic and wellness business divisions, providing both health practitioners and consumers with genomic data-driven insights with the purpose of improving people’s quality of life. The target extracts blood, tissue, saliva and/or microbiome samples, and analyzes and processes the biological data through a wholly owned laboratory that possess next generation sequencing technology and provides support through expert analysis via either medical geneticists or nutrigenetic certified nutritionists.
The press release announcing the LOI mentions Bioceres Group, an advanced life sciences platform — suggesting one of its affiliates may be the SPAC’s target. Bioceres promotes and develops disruptive technologies aligned with sustainability and human wellbeing goals, across four verticals: carbon neutrality, biomaterials, functional foods, and health and wellness. Read more.
